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Background — It is now generally accepted that calci c aortic 
valve disease is an atherosclerotic-like process. Recent studies 
in an experimental model of aortic valve sclerosis demonstrated 
the presence of tissue factor (TF), the main contributor to 
atherosclerotic plaque thrombogenicity, in diseased valve 
lea ets. We assessed the hypothesis that human aortic valve 
disease is an atherosclerotic-like process in which TF plays 
an important role and evaluated the valvular expression and 
localization of TF and other components of atherosclerosis.
Methods — Calci ed aortic valves (n=52) were obtained from patients 
undergoing aortic valve replacement. Lea et structure, cellular 
and lipid in ltration and expression of TF, its inhibitors, VEGF and 
other components of atherosclerosis were evaluated by histological 
and immunohistochemical staining. TF, TFPI, osteopontin, MMP-
9, TIMP-1 and VEGF antigen were measured by ELISA and TF and 
alkaline phosphatase activity were determined using chromogenic 
assays. Finally, we performed semi-quanti cation of TF transcripts 
by RT- PCR and further analyzed protein expression by Western 
blot.
Results — Histological and immunohistochemical staining of the 
valve lea ets revealed neovascularisation at the centre of the 
lesions, overall macrophage and myo broblast in ltration and 
the abundant presence of MMP-9. On the other hand, TF and TFPI 
were associated with calci cation and extracellular lipid deposits 
in the  brosa and the subendothelial layer of the aortic side of the 
lea ets. Correspondingly, TF antigen and activity were found to be 
higher in calci ed regions of the valve lea ets (733.29 ± 70.49 pg/
mg vs 429.40 ± 73.17 pg/mg and 144.75 ± 14.65 pg/mg vs 40.15 ± 
6.19 pg/mg respectively (p<0.0001)). Similar results were found 
for osteopontin, MMP-9, TIMP-1 and VEGF. In contrast, TFPI antigen 
was found to be much lower in these calci ed regions (722.54 ± 
153.92 pg/mg vs 2459.28 ± 285.36 pg/mg (p<0.0001)).
Conclusion — These results demonstrate that aortic valve lesions 
display several characteristics of atherosclerosis, including TF 
expression. In addition, we showed that TF is colocalized with 
calci cation and lipid deposition. Further studies are now set up to 
evaluate the role of TF in aortic valve disease and its association 
with other components of the atherosclerotic process.
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Introduction — CD163 is a macrophage receptor of haptoglogin/
haemoglobin complexes responsible for clearance of hemogloin. 
It has been recently suggested to be a potential scavenger 
receptor for TWEAK (Tumor necrosis factor-like weak inducer of 
apoptosis). TWEAK levels were reported to be decreased in carotid 
atherosclerosis. Our hypothesis is that decreased circulating 
TWEAK could be paralleled by an increased presence of CD163-
expressing macrophage in atherosclerotic plaques. Since peripheral 
artery disease (PAD) is an important manifestation of systemic 
atherosclerosis, we have assessed the levels of circulating TWEAK-
CD163 in PAD.
Methods and Results — Patients with PAD (n=184) had lower TWEAK 
(169.2±8.3 vs 211.9±15.4 pg/mL ; p<0.05) and higher sCD163 
(408.1±14.5 vs 317.4±8.4 ng/mL ; p<0.05) plasma concentration 
than age-matched controls (n=330). After strati cation according 
to the severity of disease, we observed that TWEAK/sCD163 ratio 
was signi cantly decreased in those patients with higher degree 
of disease (0.39±0.06 vs 0.66±0.08, p<0.05) relative to the other 
groups. Analysis of conditioned medium obtained from cultured 
human atherosclerotic femoral plaque samples (n=38) and healthy 
aortas (n=14) revealed that higher amount of sCD163 was released 
by the atherosclerotic tissue, whereas TWEAK presented the 
opposite trend.
Conclusions — Our results suggest that CD163/TWEAK plasma 
ratio could be a potential biomarker of clinical peripheral artery 
disease. We can hypothesized that decreased levels of circulating 
TWEAK observed in atherosclerosis may be the result of a trapping 
by plaque macrophages through their CD163.
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Purpose — Adenosine, acting through four types of receptors 
(A1, A2a, A2b, A3), is anti-in ammatory and cardioprotective. 
Since Toll-Like Receptor 4 (TLR4), a receptor involved in 
innate immunity, has recently been shown to mediate adverse 
left ventricular remodeling after myocardial infarction (MI), 
we sought to determine whether adenosine acts on the TLR4 
pathway.
Methods — Primary human macrophages obtained after in 
vitro differentiation of blood monocytes isolated from healthy 
volunteers and patients with acute MI were treated with 
adenosine (10 m), adenosine analogs, and/or lipopolysaccharide 
(LPS, 100 ng/mL). Transgenic mice bearing a cardiac-speci c and 
externally-regulatable overexpression of A1 or A2a receptors 
were used to determine the receptor involved. Flow cytometry, 
immunoblotting, quantitative PCR and ELISA were used to 
